A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

Myelodysplastic syndromes are haematopoietic stem cell neoplasms with characteristic dysplasia in the blood and bone marrow cells resulting in ineffective haematopoiesis, cytopenias, and increased ...

12. Stark AN, Scott CS, Bhatt B, Roberts B. Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia. J Clin Pathol 1986;39:728-730. 13. Bonati, A, Delia D, Starcich R. Progression of a ...

Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short By Kevin Dunleavy Jun 16, 2025 4:23pm AbbVie Roche Venclexta (venetoclax) multiple myeloma ...

By Denny Jacob. AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona).

The Myelodysplastic syndromes group at the Josep Carreras Leukaemia Research Institute has enhanced the characterisation of the first cell model capable of faithfully representing this disease.

Extreme emotional stress can cause a medical condition called broken heart syndrome. For decades, doctors thought it should mainly concern women — but that’s changing.

Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules ...

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of ...

The company's pipeline includes: HT-6184, currently in a Phase 2a trial for Myelodysplastic Syndrome (MDS); HT-6184, in combination with semaglutide, a planned Phase 2a trial in obese and Type 2 ...